Heikki Joensuu

Gastroenterology · 2001–2023

A researcher in the Science corpus: 21 papers; trusts 6 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Gastroenterology — 90 citations into it; #59 of 63 by trust here, #8 by citations
• Pulmonary and Respiratory Medicine — 67 citations into it
• Surgery — 60 citations into it
• Neurology — 14 citations into it

Whom Heikki Joensuu trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. M. Miettinen
2. J. Lasota
3. Leslie Sobin
4. C. Fletcher
5. Christopher Corless
6. M. Heinrich

Who trusts Heikki Joensuu overall

1. Christopher Corless
2. M. Heinrich

Papers from Heikki Joensuu's perspective

Ordered by how strongly the researchers Heikki Joensuu trusts endorse each paper. Same corpus, a different order for every researcher.

1. Clinical management of gastrointestinal stromal tumors: before and after STI-571. (Human Pathology)
2. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine)
3. Diagnosis of gastrointestinal stromal tumors: A consensus approach. (Human Pathology)
4. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* (Journal of Biological Chemistry)
5. Denaturing high‐performance liquid chromatography: A review (Human Mutation)
6. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. (American Journal of Pathology)
7. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. (Annals of Surgery)
8. Nonparametric Estimation from Incomplete Observations
9. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (The Journal of the National Comprehensive Cancer Network)
10. Biology of gastrointestinal stromal tumors. (Journal of Clinical Oncology)

Their papers

• FinnGen provides genetic insights from a well-phenotyped isolated population (2023) — 3,553 citations
• Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (2022) — 699 citations
• Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2021) — 871 citations
• Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. (2019) — 617 citations
• Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018) — 1,014 citations
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014) — 1,210 citations
• Gastrointestinal stromal tumour. (2013) — 809 citations
• One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. (2012) — 997 citations
• Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: an international, multicentre, prospective, randomised, placebo-controlled phase 3 trial (GRID) (2012) — 1,162 citations
• Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. (2012) — 936 citations
• Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. (2008) — 988 citations
• Risk stratification of patients diagnosed with gastrointestinal stromal tumor. (2008) — 1,193 citations
• NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. (2007) — 660 citations
• Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. (2006) — 805 citations
• Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. (2006) — 1,326 citations
• Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. (2005) — 775 citations
• Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. (2005) — 743 citations
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (2003) — 2,287 citations
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002) — 4,306 citations
• Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. (2002) — 825 citations